UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients

Critical care (London, England), 2017-08, Vol.21 (1), p.213-213, Article 213

2017

Link zum Volltext

Verfügbarkeit prüfen

Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study

Critical care medicine, 2005-05, Vol.33 (5), p.952-961

2005

Link zum Volltext

Verfügbarkeit prüfen

Severe community acquired pneumonia update: mortality, mechanisms and medical intervention

Critical care (London, England), 2008-01, Vol.12 Suppl 6 (Suppl 6), p.S1-S1

Laterre, Pierre-Francois

2008

Link zum Volltext

Verfügbarkeit prüfen

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis

Critical care medicine, 2005-08, Vol.33 (8), p.1741-1748

2005

Link zum Volltext

Verfügbarkeit prüfen

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety

Journal of critical care, 2007-06, Vol.22 (2), p.142-152

2007

Link zum Volltext

Verfügbarkeit prüfen

Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression

Case reports in anesthesiology, 2022, Vol.2022, p.3312306-4

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction: Clinical Impact of MALDI-TOF MS Identification and Rapid Susceptibility Testing on Adequate Antimicrobial Treatment in Sepsis with Positive Blood Cultures

PloS one, 2016-09, Vol.11 (9), p.e0160537-e0160537

2016

Link zum Volltext

Verfügbarkeit prüfen

Fulminant Hepatic Failure in the Course of an Outpatient Anesthetic Procedure: Sevoflurane among Other High-Risk Factors

Case reports in anesthesiology, 2020, Vol.2020, p.1-3

2020

Link zum Volltext

Verfügbarkeit prüfen

Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients

American journal of respiratory and critical care medicine, 2020-09, Vol.202 (6), p.822-829

2020

Link zum Volltext

Verfügbarkeit prüfen

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation

Critical care medicine, 2007-06, Vol.35 (6), p.1457-1463

2007

Link zum Volltext

Verfügbarkeit prüfen

Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

Expert review of anti-infective therapy, 2017-07, Vol.15 (7), p.677-688

2017

Link zum Volltext

Verfügbarkeit prüfen

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

The lancet respiratory medicine, 2023-10, Vol.11 (10), p.894-904

2023

Link zum Volltext

Verfügbarkeit prüfen

Erratum: Tracking the foreign body, a rare cause of hepatic abscess

BMC gastroenterology, 2015-02, Vol.15 (1), p.27-27, Article 27

2015

Link zum Volltext

Verfügbarkeit prüfen

Connection Between Cardiac Vascular Permeability, Myocardial Edema, and Inflammation During Sepsis: Role of the α1AMP-Activated Protein Kinase Isoform

Critical care medicine, 2013-12, Vol.41 (12), p.e411-e422

2013

Link zum Volltext

Verfügbarkeit prüfen

Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol

BMC pulmonary medicine, 2021-07, Vol.21 (1), p.1-248, Article 248

2021

Link zum Volltext

Verfügbarkeit prüfen

重症急性膵炎早期におけるプロテアーゼとプロテアーゼ阻害因子の均衡

膵臓, 2006, Vol.21(2), pp.99-101

2006

Link zum Volltext

Verfügbarkeit prüfen

COAGULATION STATUS AND RESPONSE TO TIFACOGIN IN COMMUNITY-ACQUIRED PNEUMONIA

Chest, 2005-10, Vol.128 (4), p.151S-151S

2005

Link zum Volltext

Verfügbarkeit prüfen

Re: Early Antibiotic Treatment for Severe Acute Necrotizing Pancreatitis

Annals of surgery, 2008-02, Vol.247 (2), p.394-395

2008

Link zum Volltext

Verfügbarkeit prüfen

THE SAFETY OF DROTRECOGIN ALFA (ACTIVATED): INDEPTH DATA ANALYSIS SUGGESTS SURVIVAL BENEFIT INDEPENDENT OF SERIOUS ADVERSE EVENT OCCURRENCES

Chest, 2005-10, Vol.128 (4), p.221S-221S

2005

Link zum Volltext

Verfügbarkeit prüfen

Re‐use of a liver allograft; an exceptional opportunity to enlarge the organ donor pool

Transplant international, 2003-08, Vol.16 (8), p.595-597

2003

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological Inhibition of Tissue Factor

Seminars in thrombosis and hemostasis, 2006, Vol.32 (1), p.71-76

2006

Link zum Volltext

Verfügbarkeit prüfen

Insufficient [beta]-lactam concentrations in the early phase of severe sepsis and septic shock

Critical care (London, England), 2010-07, Vol.14 (4), p.R126

2010

Link zum Volltext

Verfügbarkeit prüfen

Still Puzzled by Additional Data from the PROWESS Study

Critical care medicine, 2005-09, Vol.33 (9), p.2146-2147

2005

Link zum Volltext

Verfügbarkeit prüfen

INDEPTH DATABASE OF SEVERE SEPSIS PATIENTS SHOWS FEWER CARDIAC EVENTS IN DROTRECOGIN ALFA (ACTIVATED) PATIENTS VS PLACEBO PATIENTS

Chest, 2005-10, Vol.128 (4), p.378S-378S

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 72

Suche als RSS-Feed

Aktive Filter

KollektionJSTOR Complete Journals

ThemaAged

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients

Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study

Severe community acquired pneumonia update: mortality, mechanisms and medical intervention

LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety

Nephrogenic Diabetes Insipidus following an Off-Label Administration of Sevoflurane for Prolonged Sedation in a COVID-19 Patient and Possible Influence on Aquaporin-2 Renal Expression

Correction: Clinical Impact of MALDI-TOF MS Identification and Rapid Susceptibility Testing on Adequate Antimicrobial Treatment in Sepsis with Positive Blood Cultures

Fulminant Hepatic Failure in the Course of an Outpatient Anesthetic Procedure: Sevoflurane among Other High-Risk Factors

Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation

Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

Erratum: Tracking the foreign body, a rare cause of hepatic abscess

Connection Between Cardiac Vascular Permeability, Myocardial Edema, and Inflammation During Sepsis: Role of the α1AMP-Activated Protein Kinase Isoform

Correction to: A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol

重症急性膵炎早期におけるプロテアーゼとプロテアーゼ阻害因子の均衡

COAGULATION STATUS AND RESPONSE TO TIFACOGIN IN COMMUNITY-ACQUIRED PNEUMONIA

Re: Early Antibiotic Treatment for Severe Acute Necrotizing Pancreatitis

THE SAFETY OF DROTRECOGIN ALFA (ACTIVATED): INDEPTH DATA ANALYSIS SUGGESTS SURVIVAL BENEFIT INDEPENDENT OF SERIOUS ADVERSE EVENT OCCURRENCES

Re‐use of a liver allograft; an exceptional opportunity to enlarge the organ donor pool

Pharmacological Inhibition of Tissue Factor

Insufficient [beta]-lactam concentrations in the early phase of severe sepsis and septic shock

1557. Population Pharmacokinetics of Suvratoxumab (MEDI4893), an Extended Half-life Staphylococcus aureus Alpha Toxin-Neutralizing Human Monoclonal Antibody, in Healthy Adults and Patients on Mechanical Ventilation in Intensive Care Units

Still Puzzled by Additional Data from the PROWESS Study

INDEPTH DATABASE OF SEVERE SEPSIS PATIENTS SHOWS FEWER CARDIAC EVENTS IN DROTRECOGIN ALFA (ACTIVATED) PATIENTS VS PLACEBO PATIENTS

Aktive Filter

Suchergebnisse filtern